A retrospective investigation on the frequency of thrombotic events in 227 heterozygous and 16 homozygous carriers for the factor V R506Q mutation (factor V Leiden) from 102 unrelated families in the East Bohemian region is reported. A majority of 130 of the 227 (57%) heterozygous and a minority of 5 of 16 (31 %) homozygous carriers for the factor V R506Q mutation remained asymptomatic. Deep venous thrombosis without pulmonary embolism in a minority was the main and the most frequent clinical manifestation in 97 of 243 carriers for the factor V R506Q mutation. Deep venous thrombosis occurred in 92 of 227 (41%) heterozygous and in 11 of 16 (69%) homozygous carriers of the factor V R506Q. Spontaneous thrombosis prevailed in symptomatic men. Thrombosis in women usually occurs during risk situations well known to elicit venous thrombosis. Oral contraceptives and pregnancy were significantly the most frequent risk factors in female carriers of the factor V R506Q mutation, which in fact can readily explain the lower average age for the first thrombotic event of 30.6 years in women compared to 37.1 years in men.
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Venous thromboembolism is a major cause of morbidity and mortality in Europeans. The incidence has increased steadily and is approximately 1 per 1,000 per year (1). Thrombophilia, the clinical term for a hypercoagulable state that causes an increased tendency to thrombosis, can be either inherited or acquired. Until recently, the main genetic defects known to be associated with thromboembolism were antithrombin III, protein C, and protein S deficiency, accounting together for approximately 10% of the cases (2). In 1993, Dahlbdck et al. identified a new mechanism causing inherited thrombophilia, characterized by a poor anticoagulant response to activated protein C-APC resistance (APC-R) (3). The genetic defect underlying this phenomenon was identified as an amino acid substitution at the cleavage site of factor V gene (1691 G to A) (4). This imbalance of the hemostatic equilibrium increases the life-long risk of thrombosis 5to 10-fold in heterozygous and 50to 100-fold in homozygotes (5) . This hypercoagulable state is expressed as a risk factor associated with thrombosis (6) .
PATIENTS AND METHODS
The prevalence of APC resistance determined on the basis of examination of 500 blood donors is 1.6% in the Czech population in the East Bohemian region, representing approximately 1.2 million inhabitants. We assessed the frequency of thrombotic events among 243 individuals with APC-R and f V Leiden in the East Bohemian region.
Our group contains 243 individuals (227 heterozygous, 16 homozygous) from 102 unrelated families. Blood samples were collected by venipuncture into plastic tubes containing either 1/10 volume of 3.8% sodium citrate for APC-R assay or 1/10 volume of 0.5 sodium EDTA for DNA extraction. After double centrifugation (15 minutes at 2,500 g + 10 minutes at 1,500 g), APC-R was determined by using the Coatest APC Resistance (Chromogenix, M61ndal, Sweden) kit. Low response for APC was defined as SR < 2.05 (SRsensitivity ratio-clot time activated partial thromboplastin time + APC to activated partial thromboplastin time without APC). Amplification of genomic DNA by polymerase chain reaction followed by Mnl I restriction enzyme digestion revealed heterozygosity for the G 1691 A mutation in the factor V gene corresponding to the R 506 substitution in the factor V protein. Some studies have demonstrated an association between the presence of factor V R506Q and coronary heart disease (7) , although others have failed to shown this association (8) . Factor V Leiden was not found to be a risk factor for arterial thrombotic event in our group of 243 patients carrying the factor V R506Q mutation.
RESULTS
Resistance to APC is a common inherited factor for venous thrombosis, which is associated with a mutation in coagulation factor V (f V Leiden). Clinical manifestation is highly variable and depends on either the presence of other congenital thrombophilia markers or exposure to the risk factors.
Diagnosis of APC-R is very important not only for symptomatic individuals but also for their asymptomatic relatives. Duration of treatment with an anticoagulant after the first thrombotic event depends on two facts: whether thrombosis occurred spontaneously or during a risk situation, and how severe the sequelae of venous thrombosis will be in terms of postthrombotic venous insufficiency.
Long-term or even lifelong anticoagulant treatment is indicated in cases of recurrent thrombosis. A positive family history of thrombosis should be also taken into consideration. Prophylactic measures are recommended in asymptomatic carriers, when they are exposed to the risk factors for onset of thrombosis.
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